PharmaFocus Today – Page 91 – media

Lung cancer market battle is underway again

Recently, Ibtrozi (taletrectinib) developed by Nuvation Bio was approved by the US FDA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The drug is a highly selective, new-generation oral ROS1 tyrosine kinase inhibitor (TKI). In key trials, Ibtrozi demonstrated high response rates and lasting efficacy, and has the ability to penetrate the blood-brain barrier. Coupled with a clear and controllable safety profile, it is expected to become a new standard for targeted treatment of this type of lung cancer. It is worth noting that the drug was approved for marketing in China in December 2024 for the first-line and second-line treatment of adult patients with ROS1-positive locally advanced or metastatic NSCLC, and Innovent Biologics is responsible for commercialization. Potential BIC Therapies Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is one of the most ...
- Source: drugdu
- 170
- June 20, 2025
AstraZeneca and CSPC Pharmaceuticals reach $5.3 billion partnership

On June 13, AstraZeneca and CSPC Pharmaceutical Group reached a strategic cooperation. The two parties will focus on high-priority targets and work together to promote the discovery and development of new oral drug candidates. CSPC Pharmaceutical Group will conduct research using its AI engine dual-driven efficient drug discovery platform. The platform uses AI technology to analyze the binding mode between target proteins and existing compound molecules and conduct targeted optimization, aiming to screen out small molecules that are highly efficient and have excellent development potential. Under the agreement, CSPC Pharmaceutical Group will receive an upfront payment of US$110 million and will be eligible to receive potential research and development milestone payments of up to US$1.62 billion and potential sales milestone payments of up to US$3.6 billion, as well as potential single-digit sales commissions based on annual net sales of the relevant products. As a global pharmaceutical giant, AstraZeneca continues to ...
- Source: drugdu
- 146
- June 20, 2025
Can We Truly Cure Multiple Myeloma? Experts Say Yes

The Spanish Society of Hematology and Hemotherapy (SEHH) held its ninth “HematoAvanza” Outreach Conference at the Pazo de San Lorenzo in Santiago, Spain. The event brought together hematologists, patients, science communicators, and journalists to explore key advances in hematologic disorders, with multiple myeloma taking center stage in the discussions. María Victoria Mateos, MD, PhD, president of the SEHH, stated that “we are at the point where we can talk about curing patients with myeloma.” Mateos is also the director of the Myeloma Program and Clinical Trials Unit at the Salamanca University Hospital and an associate professor of medicine at the University of Salamanca, Salamanca, Spain. Paradigm Shift Until now, multiple myeloma has been considered an incurable disease. However, new treatments, new therapeutic strategies, and early diagnosis are making it possible to achieve a functional and even complete cure in an increasing proportion of patients. Mateos explained that the definition of ...
- Source: drugdu
- 186
- June 19, 2025
Blood Pressure Diet Helps Type 2 Diabetics

By Dennis Thompson HealthDay ReporterTUESDAY, June 17, 2025 (HealthDay News) — A diet meant to lower blood pressure also can be effective in treating type 2 diabetes after a few tweaks, a new clinical trial indicates. The DASH (Dietary Approaches to Stop Hypertension) diet effectively treated high blood pressure among type 2 diabetics, researchers reported recently in JAMA Internal Medicine. “A lot of people are interested in controlling diabetes and their blood pressure through diet and other lifestyle changes,” said senior researcher Dr. Lawrence Appel, a professor of medicine at Johns Hopkins University School of Medicine. “Most people in this study were taking more than one blood pressure medication, but we found that you can lower it further with dietary change,” Appel added in a news release. “Blood pressure is one of the most important numbers to control because the higher the number, the higher the risk of stroke and ...
- Source: drugdu
- 154
- June 19, 2025
Upgraded patent disputes with Platinum and Baiaosaitu; Rongchang Biotech’s Taitacept has been recognized as an orphan drug by the European Union

NO.1 and Platinum, Baiaosaitu Patent Dispute Escalation On the 16th, Hebo Pharmaceutical announced the latest progress of its core patent protection action to the public. The China National Intellectual Property Administration made an examination decision on June 5, 2025 to maintain the patent right of “binding molecule” with platinum medicine. The patent involves the method of preparing whole human heavy chain only antibody (HCAb) using transgenic animals, and this decision is made in response to the request for invalidation made by BIOSAITO (Beijing) Medical Technology Co., Ltd. Comment: From the previous actions, it is clear that Hebo Pharmaceutical regards this patent protection as a key measure to safeguard its core assets. The “binding molecule” patent of Platinum Pharmaceuticals is its Harbour Mice ® The core of the platform, which has established partnerships with multiple well-known pharmaceutical companies worldwide, has significant commercial value. NO.2 Yunnan Baiyao JZ-14 Capsules Obtained Clinical ...
- Source: drugdu
- 142
- June 19, 2025
Eighteen years of hard work! Breaking through with Xinkening 9, rewriting the global HPV vaccine landscape

Recently, the domestically produced nine valent HPV vaccine “Xinkening ® The approval of “9” for listing marks a crucial step for China in the field of high-end vaccine research and development. This vaccine was jointly developed by Professor Xia Ningshao’s team from Xiamen University and Wantai Biotechnology. It took 18 years to overcome numerous technical difficulties and opened up an original path for China in the international vaccine technology system. Its birth is not only an industrial breakthrough, but also an enhancement of national public health capabilities. Faced with cervical cancer, a serious threat to women’s health, China finally has an internationally advanced local protection plan. Cervical cancer has long been in the forefront of the incidence rate of malignant tumors among Chinese women, with more than 100000 new cases each year. Although vaccines are the most effective primary prevention method, the heavy reliance on expensive imported vaccines in ...
- Source: drugdu
- 213
- June 19, 2025
WALVAX and Zhiyu Biosciences reach strategic cooperation

On June 18, WALVAX announced that the company has established a strategic partnership with Shanghai Zhiyu Biotechnology Co., Ltd. (“Zhiyu Bio” for short). The core of this strategic cooperation between the two parties is to apply Zhiyu Bio’s AI modeling combined with physical simulation biocomputing technology to WALVAX’s human vaccine research and development field, focusing on using AI technology to accelerate the process development process such as protein (including enzyme) discovery and design, providing AI biocomputing platform licensing services to build intelligent R&D infrastructure, and providing deeply customized AI biocomputing solutions for the needs of specific vaccine products. https://finance.eastmoney.com/a/202506183433263559.html
- Source: drugdu
- 115
- June 19, 2025
The approval of clinical trials of innovative drugs is expected to be accelerated! The National Medical Products Administration plans to implement a 30-working-day approval system

On June 16, the State Food and Drug Administration optimized the innovative drugsThe draft for comments on clinical trial review and approval was released. It mentioned that in order to further support the research and development of innovative drugs oriented to clinical value and improve the quality and efficiency of clinical research and development, the review and approval of innovative drug clinical trial applications that meet the requirements will be completed within 30 working days. The 30-day channel for the review and approval of drug clinical trial applications supports national key research and development varieties, encourages global early synchronous research and development and international multi-center clinical trials, and serves clinical urgent needs and the development of the national pharmaceutical industry. The draft for comments proposes that applications for inclusion in the 30-day channel for the review and approval of innovative drug clinical trials should be for traditional Chinese medicines., Chemicals, ...
- Source: drugdu
- 143
- June 19, 2025
Another “patent extension king” for Chinese medicines is born

Recently, Rongchang Bio announced that it had received the “Approval Decision on Compensation for Pharmaceutical Patent Term” issued by the State Intellectual Property Office, stating that its core product, Taitasip Injection, received 1,827 days of patent compensation, and the protection period was extended from June 15, 2027 to June 15, 2032. It is worth noting that this is another case in which the pharmaceutical industry has achieved “maximum compensation” since the implementation of the new “Patent Law of the People’s Republic of my country” (hereinafter referred to as the “Patent Law”) in 2021. Institutional breakthrough Since June 1, 2021, my country’s new Patent Law has come into effect, which adds a clause on compensation for the patent term of drugs. Article 42, paragraph 3 of the Patent Law stipulates: In order to compensate for the time taken for the approval of new drug marketing, the State Council Patent Administration Department ...
- Source: drugdu
- 168
- June 19, 2025
Eight-year Takeda veteran joins BeiGene

According to reports from multiple media outlets including 21st Century Business Herald and The Paper, Shan Guohong, global senior vice president of Takeda Pharmaceutical and president of Takeda China, will step down and may join BeiGene next. 8-year veteran In September 2017, Shan Guohong became the president of Takeda China, which marked the start of Takeda China’s business boom. In 2020, Takeda China launched the “Wu Ju Future” five-year development plan, proposing the goal of launching more than 15 innovative products in China by 2025, benefiting more than 10 million Chinese patients. Under his outstanding leadership, Takeda China has climbed from the 23rd place in the foreign-invested pharmaceutical market to the 9th largest foreign-invested pharmaceutical company, becoming Takeda’s third largest market in the world, second only to the United States and Japan, and more than half of its business comes from growth pipelines and newly launched products. What is even ...
- Source: drugdu
- 136
- June 19, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.